Why is Merck spinning off Organon?
Could you elaborate on the reasoning behind Merck's decision to spin off Organon? Given Merck's leading position in the pharmaceutical industry, it seems like a significant strategic move. Are there any specific factors driving this decision, such as a change in market conditions, the need to focus on CORE businesses, or a potential for higher growth through the spin-off? Additionally, what are the potential implications for Merck and Organon in terms of financial performance, operational autonomy, and future growth prospects? I'm curious to understand the strategic rationale behind this corporate restructuring.